FDA says its safety review of abortion pill will continue into next year

The Food and Drug Administration's timeline was quickly condemned by abortion opponents hoping to see mifepristone's use curtailed.

FDA向法院提交的最新进展显示，对米非司酮的安全性审查要到2027年3月才有报告，之后才决定是否加限制，反堕胎团体对此表示不满。报道同时交代了该药的历史审批、各州诉讼与邮寄处方争议等背景。